Posaconazole tablet formulation at 400 milligrams daily achieves desired minimum serum concentrations in adult patients with a hematologic malignancy or stem cell transplant

Aaron N. Pham, Joseph S. Bubalo, James S. Lewis

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

We describe our experience using the posaconazole 400-mg delayed-release tablet formulation once daily in 20 patients with hematologic malignancy or hematopoietic stem cell transplant who were unable to attain prespecified target minimum serum (trough) concentrations for treatment or prophylaxis of invasive fungal infection. The higher dose allowed the majority of patients to achieve prespecified target trough concentrations without incurring additional toxicities.

Original languageEnglish (US)
Pages (from-to)6945-6947
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume60
Issue number11
DOIs
StatePublished - Nov 1 2016

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Posaconazole tablet formulation at 400 milligrams daily achieves desired minimum serum concentrations in adult patients with a hematologic malignancy or stem cell transplant'. Together they form a unique fingerprint.

Cite this